Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Microenvironment and Immunology

Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies

Jeff K. Davies, Harjeet Singh, Helen Huls, Dongin Yuk, Dean A. Lee, Partow Kebriaei, Richard E. Champlin, Lee M. Nadler, Eva C. Guinan and Laurence J.N. Cooper
Jeff K. Davies
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harjeet Singh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Huls
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dongin Yuk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dean A. Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Partow Kebriaei
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard E. Champlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee M. Nadler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva C. Guinan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurence J.N. Cooper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-09-3845
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Allogeneic hematopoietic stem-cell transplantation can cure some patients with high-risk B-cell malignancies, but disease relapse following transplantation remains a significant problem. One approach that could be used to augment the donor T-cell–mediated antitumor effect is the infusion of allogeneic donor–derived T cells expressing a chimeric antibody receptor (CAR) specific to the B-cell antigen CD19. However, the use of such cells might result in toxicity in the form of graft-versus-host disease mediated by CD19-specific (CD19-CAR) T cells possessing alloreactive endogenous T-cell receptors. We therefore investigated whether nonalloreactive tumor-specific human T cells could be generated from peripheral blood mononuclear cells of healthy donors by the combination of CD19 redirection via CAR expression and subsequent alloanergization by allostimulation and concomitant blockade of CD28-mediated costimulation. Alloanergization of CD19-CAR T cells resulted in efficient and selective reduction of alloresponses in both CD4+ and CD8+ T cells, including allospecific proliferation and cytokine secretion. Importantly, T-cell effector functions including CAR-dependent proliferation and specific target cytolysis and cytokine production were retained after alloanergization. Our data support the application of CD19 redirection and subsequent alloanergization to generate allogeneic donor T cells for clinical use possessing increased antitumor activity but limited capacity to mediate graft-versus-host disease. Immunotherapy with such cells could potentially reduce disease relapse after allogeneic transplantation without increasing toxicity, thereby improving the outcome of patients undergoing allogeneic transplantation for high-risk B-cell malignancies. Cancer Res; 70(10); OF1–10. ©2010 AACR.

Footnotes

    • Received October 19, 2009.
    • Revision received February 4, 2010.
    • Accepted March 1, 2010.
    • ©2010 American Association for Cancer Research.
    Next
    Back to top

    Published OnlineFirst April 27, 2010
    doi: 10.1158/0008-5472.CAN-09-3845

    Open full page PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for sharing this Cancer Research article.

    NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

    Enter multiple addresses on separate lines or separate them with commas.
    Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies
    (Your Name) has forwarded a page to you from Cancer Research
    (Your Name) thought you would be interested in this article in Cancer Research.
    Citation Tools
    Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies
    Jeff K. Davies, Harjeet Singh, Helen Huls, Dongin Yuk, Dean A. Lee, Partow Kebriaei, Richard E. Champlin, Lee M. Nadler, Eva C. Guinan and Laurence J.N. Cooper
    Cancer Res April 27 2010 DOI: 10.1158/0008-5472.CAN-09-3845

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Combining CD19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies
    Jeff K. Davies, Harjeet Singh, Helen Huls, Dongin Yuk, Dean A. Lee, Partow Kebriaei, Richard E. Champlin, Lee M. Nadler, Eva C. Guinan and Laurence J.N. Cooper
    Cancer Res April 27 2010 DOI: 10.1158/0008-5472.CAN-09-3845
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
    • Info & Metrics
    • PDF
    Advertisement

    Related Articles

    Cited By...

    More in this TOC Section

    • TLR4-Mediated Inflammation Promotes Cellular Transformation
    • CD103 Signaling in Human TRM Cells
    • Expansion of Neoclonotypes and Anti–PD-1 Clinical Efficiency
    Show more Microenvironment and Immunology
    • Home
    • Alerts
    • Feedback
    Facebook  Twitter  LinkedIn  YouTube  RSS

    Articles

    • Online First
    • Current Issue
    • Past Issues
    • Meeting Abstracts

    Info for

    • Authors
    • Subscribers
    • Advertisers
    • Librarians
    • Reviewers

    About Cancer Research

    • About the Journal
    • Editorial Board
    • Permissions
    • Submit a Manuscript
    AACR logo

    Copyright © 2018 by the American Association for Cancer Research.

    Cancer Research Online ISSN: 1538-7445
    Cancer Research Print ISSN: 0008-5472
    Journal of Cancer Research ISSN: 0099-7013
    American Journal of Cancer ISSN: 0099-7374

    Advertisement